Findings

What do systematic reviews say?

1,290 questions · 1,309 findings · 571 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,309 · 100%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

PERPHENAZINE vs placebo

Adverse events: death ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Perphenazine for schizophrenia 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Severe adverse events ‐ not reported · patients with HIV infection or exposure

The review found no eligible studies for this question.

1 finding from 1 review

Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection 2010 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Double‐dose adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation

Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma

The review found no eligible studies for this question.

1 finding from 1 review

Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antibiotics vs other antibiotics

Serious adverse events ‐ not reported · farmworkers

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic prophylaxis for leptospirosis 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antibiotics vs placebo or no intervention

Serious adverse events ‐ not reported · farmworkers, soldiers, and people in endemic areas

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic prophylaxis for leptospirosis 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Simple educational intervention vs usual care

Serious adverse events ‐ not measured · older people in all long‐term care settings

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing and reducing the use of physical restraints for older people in all long‐term care settings 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Convalescent plasma vs human immunoglobulin

Serious adverse events ‐ not reported · individuals with moderate to severe disease

The review found no eligible studies for this question.

1 finding from 1 review

Convalescent plasma for people with COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Convalescent plasma vs standard plasma

Serious adverse events ‐ not reported · outpatients withmild disease

The review found no eligible studies for this question.

1 finding from 1 review

Convalescent plasma for people with COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Class I antiarrhythmics vs control

Adverse events: thromboembolic events · Human trial participants undergoing ablation for atrial fibrillation

The review found no eligible studies for this question.

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Class I antiarrhythmics vs control

Adverse events: myocardial infarction · Human trial participants undergoing ablation for atrial fibrillation

The review found no eligible studies for this question.

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Class III antiarrhythmics vs control

Adverse events: myocardial infarction · Human trial participants undergoing ablation for atrial fibrillation

The review found no eligible studies for this question.

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oestrogen therapy alone vs pelvic floor muscle training (PFMT)

Minor adverse effects: vaginal events · women with POP

The review found no eligible studies for this question.

1 finding from 1 review

Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oestrogen therapy alone vs devices such

Minor adverse effects: vaginal events · women with POP

The review found no eligible studies for this question.

1 finding from 1 review

Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oestrogen therapy alone vs surgery

Minor adverse effects: vaginal events · women with POP

The review found no eligible studies for this question.

1 finding from 1 review

Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oestrogen therapy alone vs no treatment or placebo

Minor adverse effects: vaginal events · women with POP

The review found no eligible studies for this question.

1 finding from 1 review

Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Exercise plus usual pharmacological care vs usual pharmacological care alone

Serious adverse events ‐ not reported · systemic lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Exercise plus usual pharmacological care vs another intervention (education, joint aids, or relaxation) plus usual pharmacological care

Serious adverse events ‐ not reported · systemic lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Exercise plus usual pharmacological care vs placebo + standard care

Serious adverse events ‐ not reported · systemic lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Adverse events during study treatment · non‐hospitalised adults with mild COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

Antiplatelet agents for the treatment of adults with COVID‐19 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Adverse events during study treatment · hospitalised adults with COVID‐19 (moderate to severe disease)

The review found no eligible studies for this question.

1 finding from 1 review

Antiplatelet agents for the treatment of adults with COVID‐19 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found